Iovance Biotherapeutics (IOVA) AI Stock Analysis

• Market Cap: $1.56B
• Dividend Yield: N/A
• Average Volume (3M): 13.61M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.59
• Revenue Growth: 175.62%
• EPS Growth: 19.63%
• Country: US
• Employees: 838
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.18
• Shares Outstanding: 411,961,600
• 10 Day Avg. Volume: 20,093,408
• 30 Day Avg. Volume: 13,606,553
• PEG Ratio: 0.17
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 3.70
• P/FCF Ratio: -2.90
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 4.33
• Enterprise Value/Gross Profit: 4.45
• Enterprise Value/Ebitda: -3.16
• 1Y Price Target: $8.25
• Price Target Upside: 120.59% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): -0.61
• Revenue Forecast (FY): $414.98M

• Rating: 59 Neutral
• Price Target: $4.00 ▲(6.95% Upside)
• Action: Reiterated Date: 02/25/26
• Date: Action: Reiterated 02/25/26

The score is held back primarily by weak financials (large losses and heavy cash burn despite rapid revenue growth and improving margins). Technicals are supportive with strong trend momentum, but overbought readings raise pullback risk. Valuation is constrained by unprofitability (negative P/E), while the latest earnings call was broadly constructive on growth, margin improvement, and runway, tempered by guidance and execution risks.

Positive Factors

Commercial revenue growth

Rapid, sustained revenue scaling indicates meaningful commercial adoption of Amtagvi and Proleukin across treatment centers. Durable revenue growth supports operating leverage, funds continued R&D and commercialization investment, and underpins a path toward long‑term profitability if cost structure stays controlled.

Manufacturing internalization and capacity

Bringing manufacturing in‑house strengthens control over yield, turnaround, and unit costs — key for autologous cell therapies. Improved capacity utilization and lower dropouts support margin sustainability, supply reliability, and scalable commercialization across indications over the medium term.

Conservative balance sheet structure

A low debt load and sizable equity/assets mix give the company financial flexibility to fund clinical programs and manufacturing expansion without immediate leverage pressure. This capital structure reduces refinancing risk and helps absorb operating volatility while pursuing approvals and market expansion.

Negative Factors

Sustained negative cash flow

Persistent negative operating and free cash flow means the business cannot self‑fund growth today, increasing reliance on external financing or dilutive capital raises. Over time, this can constrain R&D and commercial expansion timing and force tradeoffs between programs if cash generation doesn't improve.

Large net losses despite growth

Substantial net losses show operating costs and SG&A remain far above current revenue despite gross margin gains. Without sustained margin improvement and cost discipline, losses can erode equity value, limit reinvestment capacity, and necessitate financing that may dilute existing shareholders.

Clinical and regulatory execution risk

Key growth depends on successful registrational trials and approvals (NSCLC, sarcoma). Small early samples and ongoing enrollment/timing risks mean outcomes and timelines are uncertain. Delays or unfavorable data would slow TAM expansion and pressure revenue and capital planning over the next 2–6 months and beyond.

Iovance Biotherapeutics Business Overview & Revenue Model

Company Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

How the Company Makes Money

Iovance Biotherapeutics generates revenue primarily through the commercialization of its cell therapy products, including lifileucel, once approved by regulatory authorities. The company also engages in partnerships and collaborations with larger pharmaceutical companies for research and development support, which can include upfront payments, milestone payments, and royalties on future sales. Additionally, Iovance may receive funding through grants or other financial support aimed at advancing its clinical programs. The successful transition of its products from clinical trials to market approval is crucial for its revenue generation.

Iovance Biotherapeutics Financial Statement Overview

Summary

Revenue growth is strong (to ~$263.5M in 2025) and gross margin improved materially, but the company remains deeply unprofitable (2025 net loss ~$391M) with significant ongoing cash burn (2025 operating cash flow about -$302M; free cash flow about -$336M). Low debt and sizable equity provide flexibility, yet sustained losses and burn remain the core financial risk.

Income Statement

Revenue has scaled meaningfully in recent years (from near-zero to $164.1M in 2024 and $263.5M in 2025), and gross margin improved sharply to ~97% in 2025. However, the company remains deeply unprofitable with a 2025 net loss of ~$391.0M and negative operating profitability, indicating operating costs are still far ahead of the current revenue base.

Balance Sheet

The balance sheet is relatively conservative for a biotech: debt is low at ~$48.4M in 2025 with a low debt-to-equity ratio (~0.07), supported by ~$698.6M of equity and ~$913.2M of assets. The key weakness is sustained losses driving materially negative returns on equity, which can pressure the capital base over time if profitability does not improve.

Cash Flow

Cash generation remains a clear weak point: operating cash flow was negative in each year shown, including about -$302.4M in 2025, and free cash flow was also negative at about -$336.2M. While cash burn improved versus 2024 (less negative operating and free cash flow), free cash flow declined year over year in 2025 and the business still relies on funding to bridge ongoing losses and investment needs.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	263.50M	164.07M	1.19M	0.00	0.00
Gross Profit	256.22M	40.08M	-9.57M	0.00	0.00
EBITDA	-357.11M	-351.67M	-427.43M	-377.74M	-328.72M
Net Income	-390.98M	-372.18M	-444.04M	-395.89M	-342.25M
Balance Sheet
Total Assets	913.17M	910.43M	780.35M	663.98M	777.33M
Cash, Cash Equivalents and Short-Term Investments	296.98M	323.78M	279.87M	471.85M	504.41M
Total Debt	48.44M	58.26M	75.86M	85.45M	71.53M
Total Liabilities	214.59M	200.02M	195.74M	164.34M	155.67M
Stockholders Equity	698.58M	710.40M	584.61M	499.64M	621.66M
Cash Flow
Free Cash Flow	-336.24M	-364.05M	-384.11M	-313.18M	-265.51M
Operating Cash Flow	-302.41M	-352.98M	-361.82M	-292.76M	-227.94M
Investing Cash Flow	47.50M	-96.41M	-155.24M	256.45M	132.00K
Financing Cash Flow	300.77M	390.66M	462.96M	190.15M	239.27M

Iovance Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.74
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOVA, the sentiment is Positive. The current price of 3.74 is above the 20-day moving average (MA) of 2.92, above the 50-day MA of 2.73, and above the 200-day MA of 2.35, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 75.62 is Negative, neither overbought nor oversold. The STOCH value of 70.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IOVA.

Iovance Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VIR	64 Neutral	$1.47B	―	-45.73%	―	-78.55%	7.74%
IOVA	59 Neutral	$1.56B	-3.38	-55.50%	―	175.62%	19.63%
KALV	57 Neutral	$811.77M	-4.02	―	―	―	-13.14%
IMTX	56 Neutral	$1.34B	-9.14	-29.00%	―	-27.61%	-69.49%
AMLX	55 Neutral	$1.68B	-8.50	-56.52%	―	-100.34%	52.85%
NUVB	52 Neutral	$2.01B	―	-52.49%	―	1137.19%	70.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Iovance Biotherapeutics Corporate Events

Iovance Highlights Amtagvi Revenue Growth and Profitability Path

On February 24, 2026, Iovance Biotherapeutics reported that 2025 was its first full calendar year of Amtagvi launch, delivering about 30% sequential fourth-quarter revenue growth to roughly $87 million and full-year product revenue of about $264 million, in line with guidance. Gross margin improved to about 50%, the company ended 2025 with about $303 million in cash expected to fund operations into the third quarter of 2027, and operational initiatives such as fully internalizing lifileucel manufacturing are aimed at further lowering costs and supporting a path toward profitability.

In 2025, U.S. Amtagvi sales reached about $220 million and Proleukin about $44 million, supported by a growing network of authorized treatment centers, faster 32-day-or-less manufacturing turnaround, and real-world and trial data showing unprecedented response rates and durable benefit in advanced melanoma. The company advanced its pipeline with U.S. FDA Fast Track designation for lifileucel in second-line advanced non-small cell lung cancer, positive interim NSCLC data suggesting a best-in-class profile versus docetaxel, plans for a potential U.S. accelerated approval in 2027, and progress across multiple trials and new indications including sarcomas, frontline melanoma combinations, and next-generation engineered TIL therapies, reinforcing its positioning as a leader in TIL-based cancer treatment.

The most recent analyst rating on (IOVA) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Highlights Amtagvi Momentum and Confirms 2025 Guidance

On January 9, 2026, Iovance Biotherapeutics updated its corporate presentation, indicating that it expected to meet its previously disclosed full-year 2025 revenue guidance of $250 million to $300 million in the first full calendar year of Amtagvi sales. The presentation highlighted that total revenue since the first quarter of 2024 had reached about $340 million as of September 30, 2025, with approximately $307 million in cash on hand, more than 85 treatment centers in the U.S. and Canada and multiple global markets engaged, and improving gross margins following organizational streamlining. Iovance emphasized its leadership in TIL-based cell therapy, the commercial momentum of Amtagvi in advanced melanoma with real-world response rates around 50%, and the potential for substantial future growth driven by ongoing registration-directed trials in metastatic non-small cell lung cancer and other solid tumors, positioning the company as a key player in next-generation oncology cell therapies.

The most recent analyst rating on (IOVA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.